ASCRS

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Retrieved on: 
Dienstag, Juli 18, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, Surgery, Health, FDA, Clinical Trials, DED, Harald von Boehmer, University, Therapy, Patient satisfaction, Efficacy, Sheppard, Eye, Telecanthus, Pharmacokinetics, ASCRS, Multimedia, Inflammation, Cornea, Random phase approximation, Stinger, Ophthalmology, Acquisition, Oil, Patient, BID, Political moderate, University of Pikeville, Ciclosporin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Treatment, Food, JAMA Ophthalmology, Pharmaceutical industry, Safety

“VEVYE, which is expected to be available soon, is a unique cyclosporine formulation indicated for treatment of the signs and symptoms of DED.

Key Points: 
  • “VEVYE, which is expected to be available soon, is a unique cyclosporine formulation indicated for treatment of the signs and symptoms of DED.
  • In this study, VEVYE was shown to be safe, and no systemic exposure of cyclosporin was observed after ocular administration.
  • Schirmer’s tear test responses of ≥10 mm increase was statistically significantly higher in the VEVYE compared vehicle at Day 29.
  • Wirta DL, Krösser S, Long -Term Safety and Efficacy of a Water-Free Cyclosporine Ophthalmic Solution for the Treatment of Dry‑Eye Disease: ESSENCE-2-OLE study.

Ocular Therapeutix™ Announces Appointment of New Board Member

Retrieved on: 
Mittwoch, Juli 12, 2023
Opus, University, Refractive surgery, Doctor of Philosophy, Emeritus, Stanford University, Eye, Himalayan Cataract Project, Research, ASCRS, RD, Ophthalmic, The Many Ghosts of Doctor Graves, Grave, Ophthalmology, OWL, Alcon, Brown University, ISCB Senior Scientist Award, Akorn, FFB, Cataract, Therapy, Society, Pharmaceutical industry, Management, Psychology

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.

Key Points: 
  • BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Adrienne L. Graves, Ph.D., to its Board of Directors.
  • A visual scientist by training and a global industry leader in ophthalmology, Dr. Graves brings extensive experience to her role.
  • Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory.
  • She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.

Four OCLI Vision Doctors Named Among Newsweek's America's Best Eye Doctors of 2023 including the Top Spot

Retrieved on: 
Mittwoch, Juli 5, 2023
Cornea, Surgeon, Refractive surgery, Surgery, Lecture, Hospital, Eye, Lions Eye Bank, American Academy, American Academy of Ophthalmology, Research, ASCRS, Macdonald, Optometry, American Society of Cataract and Refractive Surgery, MD, Patient, Microsurgery, Cataract, Society, Medical device, Nursing, Dentistry, Newsweek, Ophthalmology, Medal

NEW YORK, July 5, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is delighted to announce that Dr. Eric Donnenfeld, Dr. Richard Mackool, Dr. Marguerite McDonald, and Dr. Henry Perry have all once again been recognized on Newsweek's America's Best Eye Doctors 2023 list. This marks the third consecutive year that Dr. Donnenfeld, a nationally and internationally acclaimed ophthalmologist, is named in this annual ranking as the top ophthalmologist in the country.

Key Points: 
  • OCLI Vision, supported by Spectrum Vision Partners, is a leading ophthalmology practice serving multiple states.
  • NEW YORK, July 5, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is delighted to announce that Dr. Eric Donnenfeld, Dr. Richard Mackool, Dr. Marguerite McDonald, and Dr. Henry Perry have all once again been recognized on Newsweek's America's Best Eye Doctors 2023 list.
  • All of us at OCLI Vision send our most heartfelt congratulations to Dr. Donnenfeld, Dr. Mackool, Dr. McDonald, and Dr.
  • OCLI Vision is a premier ophthalmology practice that continues to grow and excel, supported by Spectrum Vision Partners' management and administrative services.

Activ Surgical® Presented Findings from Colorectal Study Using its ActivSight™ Intelligent Light at the American Society of Colon and Rectal Surgeons Annual Scientific Meeting

Retrieved on: 
Montag, Juni 5, 2023
Technology, Surgery, Medical Devices, Hospitals, Health Technology, Software, Hardware, Health, Robotics, Ohio State University, Medicine, Surgeon, Laser speckle contrast imaging, Comparison, Rectum, Perfusion, Intelligent lighting, ASCRS, American Society of Colon and Rectal Surgeons, LOD, Doctor of Philosophy, Trial of the century, OSU, MD, Division, Ohio State University Wexner Medical Center, Patient safety, FDA, Society, ICG, Dissection, Medical imaging, Dentistry, Indocyanine green

Activ Surgical , a digital surgery pioneer, presented findings today at The American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting from a clinical study conducted at The Ohio State University Wexner Medical Center using the ActivPerfusion™ and ActivICG™ modes within its FDA cleared product, ActivSight™ Intelligent Light (ActivSight).

Key Points: 
  • Activ Surgical , a digital surgery pioneer, presented findings today at The American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting from a clinical study conducted at The Ohio State University Wexner Medical Center using the ActivPerfusion™ and ActivICG™ modes within its FDA cleared product, ActivSight™ Intelligent Light (ActivSight).
  • LSCI provides real-time tissue perfusion information by measuring coherent laser light scatter from moving red blood cells.
  • For cases where a decision was changed, the average discordance between the line of demarcation (LOD) in white light imaging and LSCI was 3.7cm.
  • “Less dissection and removal of tissue can improve patient safety and may lead to better surgical outcomes.”

Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer™ for the Treatment of Dry Eye Disease

Retrieved on: 
Donnerstag, Juni 8, 2023
Agreement, DED, Partnership, ASEAN, Refraction, Drug discovery, New Drug Application, Vibration, NDA, Good, Wafer, Research, ASCRS, MS, Trial of the century, U.S. FDA, Telecanthus, Incidence, Ophthalmology, American Society of Cataract and Refractive Surgery, Benjamin, Eyelid, Meibomian gland dysfunction, Patient, SEHK, ELM, Gland, Cataract, FDA, Society, Pharmaceutical industry, Tmall, MD, Greater China

By uniquely combining several mechanisms, ELM delivers heat to the eyelids to lower the viscosity of the oil (i.e.

Key Points: 
  • By uniquely combining several mechanisms, ELM delivers heat to the eyelids to lower the viscosity of the oil (i.e.
  • We always strive to deliver the best treatment options with a combination of drugs and medical devices to patients.
  • With the ELM, we have reimagined dry eye treatment, and have created a solution that is remarkably effective, affordable, and convenient.
  • Eyedetec Medical, Inc., is a medical device company with a mission to research and develop a portfolio of novel technologies to address the growing problem of dry eye disease.

Virtual Incision Announces MIRA’s Clinical Trial Results Will Be Presented at the 2023 ASCRS Scientific Meeting

Retrieved on: 
Mittwoch, Mai 31, 2023
Technology, FDA, Health, Robotics, Health Technology, Medical Devices, Research, Surgery, Science, Hardware, Clinical Trials, Investigational device exemption, Surgeon, De novo, Marketing, Main Line Health, Clinical trial, Lankenau Medical Center, ASCRS, Lankenau Institute for Medical Research, American Society of Colon and Rectal Surgeons, Colorectal surgery, Hospital, RAS, MIRA, IDE, Society, Medical research, Safety, Dentistry

Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.

Key Points: 
  • Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.
  • The study was designed to evaluate the safety and efficacy of MIRA for use in bowel resection procedures.
  • John Marks will unveil the full patient data set to his peer group for the very first time,” said John Murphy, president and chief executive officer of Virtual Incision.
  • Virtual Incision is the first RAS developer to complete a U.S. IDE study to support a De Novo request in bowel resection.

Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses

Retrieved on: 
Mittwoch, Mai 31, 2023
Dysphagia, Pharmacy, Metastasis, Abiraterone acetate, PDT, ASCRS, American Society of Colon and Rectal Surgeons, ASCO, American Society of Clinical Oncology, Anal, Patient, Alternative, Annual general meeting, Anal fissure, Poster, CDT, FDA, Therapy, Society, Potential, Pharmaceutical industry

"At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.

Key Points: 
  • "At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.
  • Currently, non-surgical options to treat anal fissures include topical nitrates (which are limited by headache/tolerability) and topical calcium channel blockers (which are only available via compounding pharmacies as none are FDA-approved for anal fissure).
  • Based on the data that will be presented, we believe that TAVT-119 has the potential to offer patients a therapeutic option that is safe, efficacious and accessible."
  • "We are pleased to highlight these promising new data, which reflect the significant progress of our clinical development programs," said Lynne Powell, Chief Executive Officer of Tavanta Therapeutics.

Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness

Retrieved on: 
Dienstag, Mai 16, 2023
ARVO, Refractive surgery, Eye, Corneal opacity, Allotransplantation, ASCRS, American Society of Cataract and Refractive Surgery, Opacity (optics), Patient, SAN, CLARITY, Association for Research in Vision and Ophthalmology, Paratriathlon, Research, Cataract, III, Society, ALK, Veterinary medicine, Vaccine, Ophthalmology

SUZHOU, China and SAN FRANCISCO, May 16, 2023 /PRNewswire/ -- Eluminex Biosciences (Eluminex) announced that its clinical pivotal study (CLARITY) evaluating a novel biosynthetic corneal implant (EB-301) currently being conducted in China was recognized for its groundbreaking work at two recent international ophthalmology meetings held in the United States.

Key Points: 
  • Eluminex's poster presentation entitled "A novel recombinant human collagen III (rhCIII) biosynthetic cornea (EB-301) to treat corneal blindness: initial results of the CLARITY Study" (poster 88312) presented on May 7, 2023, received honorable mention recognition in the category of Cornea.
  • The ASCRS annual meeting is an internationally recognized scientific symposium for clinicians and researchers in the field of cataract, refractive, cornea and glaucoma surgery.
  • The EB-301 investigational corneal implant is manufactured from recombinant human Type III collagen (rhCIII) and is intended to treat corneal blindness secondary to stromal lesions amenable to anterior lamellar keratoplasty (ALK) surgery as an alternative to human cadaveric corneal transplants.
  • Corneal blindness is a leading cause of vision loss globally; however, it is estimated that over half the world's population has no access to a corneal transplant.

Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Montag, Mai 15, 2023
Insurance, Interim, ARVO, Refractive surgery, DLD, Clinical trial, Presbyopia, NDA, DRSS, Research, ASCRS, American Society of Cataract and Refractive Surgery, OCUP, Patient, Risk, Annual general meeting, Diabetic retinopathy, Association for Research in Vision and Ophthalmology, Security (finance), Cataract, FDA, Safety, Society, Pharmaceutical industry, Veterinary medicine, Cryptocurrency, DR, RM, Ophthalmology, PDUFA

FARMINGTON HILLS, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • “Ocuphire made significant progress across both our APX3330 and Nyxol programs throughout the first quarter,” said Rick Rodgers, Interim Chief Executive Officer.
  • First Quarter ended March 31, 2023 Financial Highlights
    As of March 31, 2023, Ocuphire had cash and cash equivalents of approximately $39.0 million.
  • The loss from operations for the quarter ended March 31, 2023 was $6.1 million, compared to $6.5 million for the quarter ended March 31, 2022.
  • For further details on Ocuphire’s financial results, refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the Securities and Exchange Commission.

Harrow Announces First Quarter 2023 Financial Results

Retrieved on: 
Donnerstag, Mai 11, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, Surgery, Health, FDA, Clinical Trials, Growth, Letter, EBITDA, Multimedia, ASCRS, Pharmaceutical industry, Fine chemical

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the first quarter ended March 31, 2023.

Key Points: 
  • Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the first quarter ended March 31, 2023.
  • The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com .
  • “We are pleased that our Harrow team delivered record revenues of $26.1 million, a 28% increase over the fourth quarter of 2022, but, even more important, we see the first quarter of 2023 marking the beginning of a new revenue paradigm for Harrow.
  • “We believe our successful first quarter is indicative of 2023 being a catalyst-rich year for Harrow, including our recent launch of IHEEZO™ at ASCRS in San Diego.